203805-85-0

203805-85-0 structure

Name: Allopregnanolone-d4
Chemical Name: (3α,5α,8α)-3-Hydroxy(1,2,2,3-2H4)pregnan-20-one
CAS Number: 203805-85-0
Molecular Formula: C₂₁H₃₀D₄O₂
Molecular Weight: 322.518
Create Date: 2018-02-17 19:41:50
Modify Date: 2024-01-03 09:48:59
Allopregnanolone-d4 is the deuterium labeled Allopregnanolone. Allopregnanolone (Brexanolone), a metabolite of progesterone, is a positive allosteric modulator of GABAA receptors. Allopregnanolone modulates dopamine levels in the nucleus accumbens and prefrontal cortex. Allopregnanolone stimulates food intake and weight gain[1].

Name	(3α,5α,8α)-3-Hydroxy(1,2,2,3-2H4)pregnan-20-one
Synonyms	(3α,5α,8α)-3-Hydroxy(1,2,2,3-H)pregnan-20-one Pregnan-20-one-1,2,2,3-d, 3-hydroxy-, (3α,5α,8α)-

Description	Allopregnanolone-d4 is the deuterium labeled Allopregnanolone. Allopregnanolone (Brexanolone), a metabolite of progesterone, is a positive allosteric modulator of GABAA receptors. Allopregnanolone modulates dopamine levels in the nucleus accumbens and prefrontal cortex. Allopregnanolone stimulates food intake and weight gain[1].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> GABA Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Dornellas APS, et al. Allopregnanolone Decreases Evoked Dopamine Release Differently in Rats by Sex and Estrous Stage. Front Pharmacol. 2021;11:608887. Published 2021 Jan 14. [3]. Kimball A, et al. The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause. Psychoneuroendocrinology. 2020;112:104512.